Rajabally, Yusuf A.
Stettner, Mark
Kieseier, Bernd C.
Hartung, Hans-Peter
Malik, Rayaz A.
Article History
First Online: 15 September 2017
Competing interests
: Y.A.R. has received speaker and/or consultancy honoraria from CSL Behring, LfB, Grifols, BPL, Octapharma and Kedrion, has received educational sponsorships from LfB, CSL Behring and Baxter, and has obtained research grants from CSL Behring and LfB. M.S. has received honoraria for consulting or lecturing and travel expenses for attending meetings from Biogen Idec, Genzyme, Novartis, Sanofi Aventis, UCB, Grifols and TEVA, and has received financial support for research from Bayer Health Care and UCB. B.C.K. has received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Health Care, Biogen, Genzyme/Sanofi Aventis, Grifols, Merck Serono, Mitsubishi Europe, Novartis, Roche, Talecris and TEVA. He is currently also an employee of Biogen. H.-P.H. has received fees for consulting, speaking and serving on steering committees from Baxelta, CSL Behring, Kedrion, Novartis, Octapharma and LfB. R.A.M. has received honoraria for speaking or consultancy from Pfizer, Lilly and Novo Nordisk.